Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI.
Saved in:
| Title: | Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non–Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI. |
|---|---|
| Authors: | Hye Ryeon Kim1,2, Hyunji Jo1, Hongsik Kim1, Joohyun Hong1, Sehhoon Park1, Hyun Ae Jung1, Se-Hoon Lee1, Jin-Seok Ahn1, Myung-Ju Ahn1 |
| Source: | Cancer Research & Treatment. Jan2023, Vol. 55 Issue 1, p344-349. 6p. |
| Database: | Academic Search Ultimate |
| ISSN: | 15982998 |
|---|---|
| DOI: | 10.4143/crt.2021.1603 |
